骨髓增生异常综合征

Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81:104-130.

• 摘要

Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6:902-926.

• 摘要

Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009:645-655.

• 全文
• 摘要

Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:58-77.

• 摘要

Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother. 2008;9:1667-1678.

• 摘要

Fey MF, Dreyling M; ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v158-v161.

• 全文
• 摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. http://www.nccn.org/ (last accessed 18 September 2017).

• 全文

Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.

• 摘要

Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008;87:527-536.

• 摘要

Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12:1264-1273.

• 全文
• 摘要

Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008;32:1338-1353.

• 摘要

1.  Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.

• 全文
• 摘要

2.  Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

3.  Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788-793.

• 摘要

4.  Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med. 1991;90:338-344.

• 摘要

5.  Enright H, Jacobs HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995;91:403-408.

• 摘要

6.  Finelli CC. The myelodysplastic syndromes: Diagnosis, prognosis and therapy. Ital J Med. 2011;5:90-97.

7.  Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358-367.

• 摘要

8.  Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(Suppl 1):258-269.

• 摘要

9.  Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005;19:767-775.

• 全文
• 摘要

10.  Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81:104-130.

• 摘要

11.  Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71-86.

• 摘要

12.  West RR, Stafford DA, Farrow A, et al. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res. 1995;19:127-139.

• 摘要

13.  Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6:902-926.

• 摘要

14.  Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009:645-655.

• 全文
• 摘要

15.  Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-1660.

• 摘要

16.  Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264-268.

• 全文
• 摘要

17.  Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome: acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99:822-824.

• 全文
• 摘要

18.  Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-2465.

• 全文
• 摘要

19.  Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510.

• 全文
• 摘要

20.  Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:58-77.

• 摘要

21.  Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother. 2008;9:1667-1678.

• 摘要

22.  Fey MF, Dreyling M; ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v158-v161.

• 全文
• 摘要

23.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. http://www.nccn.org/ (last accessed 18 September 2017).

• 全文

24.  Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.

• 摘要

25.  Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009;15:137-172.

• 摘要

26.  Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2008;87:527-536.

• 摘要

27.  Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist. 2007;12:1264-1273.

• 全文
• 摘要

28.  Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010;34:1576-1588.

• 摘要

29.  Miller W, Holden J, George E, et al. NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. Lancet Oncol. 2011;12:326-327.

• 摘要

30.  Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome: a systematic review and meta-analysis. Haematologica. 2010;95:303-310.

• 全文
• 摘要

31.  National Institute for Health and Care Excellence. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia. March 2011. http://www.nice.org.uk/ (last accessed 3 July 2017).

• 全文

32.  Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987-1996.

• 摘要

33.  Sekeres MA. Lenalidomide in MDS: 4th time's a charm. Blood. 2011;118:3757-3758.

• 摘要

34.  Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765-3776.

• 摘要

35.  Leitch HA, Buckstein R, Shamy A, et al. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Crit Rev Oncol Hematol. 2013;85:162-192.

• 全文
• 摘要

36.  Stasi R, Amadori S, Newland AC, et al. Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma. 2005;46:509-516.

• 摘要

37.  Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010;149:706-710.

• 全文
• 摘要

38.  Sekeres MA. Arsenic trioxide as a treatment for myelodysplastic syndrome. Curr Hematol Malig Rep. 2006;1:34-38.

• 摘要

39.  Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008;15 Suppl:40-49.

• 全文
• 摘要

40.  Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116:3163-3170.

• 全文
• 摘要

41.  Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120:1838-1846.

• 全文
• 摘要

42.  Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. [Erratum in: Blood. 1998;91:1100.]

• 全文
• 摘要

43.  Haider M, Duncavage EJ, Afaneh KF, et al. New insight into the biology, risk stratification, and targeted treatment of myelodysplastic syndromes. Am Soc Clin Oncol Educ Book. 2017;37:480-494.

• 全文
• 摘要

44.  Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288-299.

• 摘要

45.  Galanello R, Campus S, Origa R, et al. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012;8:123-134.

• 摘要

46.  Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008;32:1338-1353.

• 摘要